Evaluation of prognostic values of tissue plasminogen activator and plasminogen activator inhibitor-1 in crimean-congo hemorrhagic fever patients

Jundishapur Journal of Microbiology

Volumn 8, Issue 10, 2015, Pages

  Gurbuz, Yunus ^a   Ozturk, Baris ^b   Tutuncu, Emin Ediz ^a   Sencan, Irfan ^a   Senturk, Gonul Cicek ^a   Altay, Fatma Aybala ^a  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b MINISTRY OF HEALTH   (Turkey)

Author keywords

Crimean congo hemorrhagic fever; Plasminogen activator inhibitor 1; Tissue plasminogen activator

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; FIBRINOGEN; IMMUNOGLOBULIN M; LACTATE DEHYDROGENASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; PARTIAL THROMBOPLASTIN TIME; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROGNOSIS; PROTEIN DETERMINATION; PROTHROMBIN TIME; THROMBOCYTE;

EID: 84944474450     PISSN: 20083645     EISSN: 20084161     Source Type: Journal    
DOI: 10.5812/jjm.26514     Document Type: Article

References (28)

1. Ergonul O, Celikbas A, Dokuzoguz B, Eren S, Baykam N, Esener H. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis. 2004;39(2):284-7. doi: 10.1086/422000. [PubMed: 15307042]
2. Leblebicioglu H. Crimean-Congo haemorrhagic fever in Eurasia. Int J Antimicrob Agents. 2010;36 Suppl 1:S43-6. doi: 10.1016/j.ijantimicag.2010.06.020. [PubMed: 20810253]
3. Whitehouse C. Crimean?Congo hemorrhagic fever. Antiviral Res. 2004;64(3):145-60. doi: 10.1016/j.antiviral.2004.08.001. [PubMed: 15550268]
4. Gunes T, Poyraz O, Vatansever Z. Crimean-Congo hemorrhagic fever virus in ticks collected from humans, livestock, and picnic sites in the hyperendemic region of Turkey. Vector Borne Zoonotic Dis. 2011;11(10):1411-6. doi: 10.1089/vbz.2011.0651. [PubMed: 21736490]
5. Bakir M, Ugurlu M, Dokuzoguz B, Bodur H, Tasyaran MA, Vahaboglu H, et al. Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures. J Med Microbiol. 2005;54(Pt 4):385-9. doi: 10.1099/jmm.0.45865-0. [PubMed: 15770025]
6. Ergönül Ö. Crimean-Congo haemorrhagic fever. Lancet Infect Dis. 2006;6(4):203-14. doi: 10.1016/s1473-3099(06)70435-2. [PubMed: 16554245]
7. Akinci E, Bodur H, Leblebicioglu H. Pathogenesis of Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis. 2013;13(7):429-37. doi: 10.1089/vbz.2012.1061. [PubMed: 23663164]
8. Weber F, Mirazimi A. Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus; an emerging and neglected viral zonoosis. Cytokine Growth Factor Rev. 2008;19(5-6):395-404. doi: 10.1016/j.cytogfr.2008.11.001. [PubMed: 19027345]
9. Ergonul O, Tuncbilek S, Baykam N, Celikbas A, Dokuzoguz B. Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever. J Infect Dis. 2006;193(7):941-4. doi: 10.1086/500836. [PubMed: 16518755]
10. Papa A, Bino S, Velo E, Harxhi A, Kota M, Antoniadis A. Cytokine levels in Crimean-Congo hemorrhagic fever. J Clin Virol. 2006;36(4):272-6. doi: 10.1016/j.jcv.2006.04.007. [PubMed: 16765637]
11. Ozturk B, Kuscu F, Tutuncu E, Sencan I, Gurbuz Y, Tuzun H. Evaluation of the association of serum levels of hyaluronic acid, sICAM-1, sVCAM-1, and VEGF-A with mortality and prognosis in patients with Crimean-Congo hemorrhagic fever. J Clin Virol. 2010;47(2):115-9. doi: 10.1016/j.jcv.2009.10.015. [PubMed: 20005156]
12. Chuang YC, Lin YS, Liu CC, Liu HS, Liao SH, Shi MD, et al. Factors contributing to the disturbance of coagulation and fibrinolysis in dengue virus infection. J Formos Med Assoc. 2013;112(1):12-7. doi: 10.1016/j.jfma.2012.10.013. [PubMed: 23332424]
13. Djamiatun K, Faradz SM, Setiati TE, Netea MG, van der Ven AJ, Dolmans WM. Increase of plasminogen activator inhibitor-1 and decrease of transforming growth factor-b1 in children with dengue haemorrhagic fever in Indonesia. J Trop Pediatr. 2011;57(6):424-32. doi: 10.1093/tropej/fmq122. [PubMed: 21278057]
14. Rachman A, Rinaldi I. Coagulopathy in dengue infection and the role of interleukin-6. Acta Med Indones. 2006;38(2):105-8. [PubMed: 16799214]
15. Yilmaz GR, Buzgan T, Irmak H, Safran A, Uzun R, Cevik MA, et al. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002-2007. Int J Infect Dis. 2009;13(3):380-6. doi: 10.1016/j. ijid.2008.07.021. [PubMed: 18986819]
16. Swanepoel R, Gill DE, Shepherd AJ, Leman PA, Mynhardt JH, Harvey S. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis. 1989;11 Suppl 4:S794-800. [PubMed: 2749111]
17. Bakir M, Gozel MG, Koksal I, Asik Z, Gunal O, Yilmaz H, et al. Validation of a severity grading score (SGS) system for predicting the course of disease and mortality in patients with Crimean- Congo hemorrhagic fever (CCHF). Eur J Clin Microbiol Infect Dis. 2015;34(2):325-30. doi: 10.1007/s10096-014-2238-0. [PubMed: 25213721]
18. Ergonul O, Celikbas A, Baykam N, Eren S, Dokuzoguz B. Analysis of risk-factors among patients with Crimean-Congo haemorrhagic fever virus infection: severity criteria revisited. Clin Microbiol Infect. 2006;12(6):551-4. doi: 10.1111/j.1469-0691.2006.01445.x. [PubMed: 16700704]
19. Cevik MA, Erbay A, Bodur H, Gulderen E, Bastug A, Kubar A, et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J Infect Dis. 2008;12(4):374-9. doi: 10.1016/j.ijid.2007.09.010. [PubMed: 18063402]
20. Tasdelen Fisgin N, Tanyel E, Doganci L, Tulek N. Risk factors for fatality in patients with Crimean-Congo haemorrhagic fever. Trop Doct. 2009;39(3):158-60. doi: 10.1258/td.2008.080092. [PubMed: 19535753]
21. Ozturk B, Tutuncu E, Kuscu F, Gurbuz Y, Sencan I, Tuzun H. Evaluation of factors predictive of the prognosis in Crimean- Congo hemorrhagic fever: new suggestions. Int J Infect Dis. 2012;16(2):e89-93. doi: 10.1016/j.ijid.2011.06.005. [PubMed: 22154082]
22. Jiang Z, Tang X, Xiao R, Jiang L, Chen X. Dengue virus regulates the expression of hemostasis-related molecules in human vein endothelial cells. J Infect. 2007;55(2):e23-8. doi: 10.1016/j. jinf.2007.04.351. [PubMed: 17573116]
23. Huang Y, Liu C, Wang S, Lei H, Liu H, Lin Y, et al. Activation of coagulation and fibrinolysis during dengue virus infection. J Med Virol. 2001;63(3):247-51. doi: 10.1002/1096-9071(200103)63:3<247::aid-jmv1008>3.0.co;2-f. [PubMed: 11170065]
24. Shyu HW, Lin YY, Chen LC, Wang YF, Yeh TM, Su SJ, et al. The dengue virus envelope protein induced PAI-1 gene expression via MEK/ERK pathways. Thromb Haemost. 2010;104(6):1219-27. doi: 10.1160/TH10-05-0302. [PubMed: 20886187]
25. Sosothikul D, Seksarn P, Pongsewalak S, Thisyakorn U, Lusher J. Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection. Thromb Haemost. 2007. doi: 10.1160/th06-02-0094.
26. Wills BA, Oragui EE, Stephens AC, Daramola OA, Dung NM, Loan HT, et al. Coagulation abnormalities in dengue hemorrhagic Fever: serial investigations in 167 Vietnamese children with Dengue shock syndrome. Clin Infect Dis. 2002;35(3):277-85. doi: 10.1086/341410. [PubMed: 12115093]
27. Heller MV, Marta RF, Sturk A, Maiztegui JI, Hack CE, Cate JW, et al. Early markers of blood coagulation and fibrinolysis activation in Argentine hemorrhagic fever. Thromb Haemost. 1995;73(3):368-73. [PubMed: 7667817]
28. Huang YH, Lei HY, Liu HS, Lin YS, Chen SH, Liu CC, et al. Tissue plasminogen activator induced by dengue virus infection of human endothelial cells. J Med Virol. 2003;70(4):610-6. doi: 10.1002/ jmv.10438. [PubMed: 12794725]